Restoring what disease has taken: Where the mind goes, the body follows
We are developing a fully implantable AI system that decodes neural signals into natural speech and movement, restoring communication and independence to those who have lost them.
Our Mission
To develop and deliver a fully implantable brain-computer interface platform that restores communication and movement — and with them, the connection to loved ones and the world.
Our Vision
A world where neurological conditions no longer silence the human voice or sever the connection between mind and body. We envision neuroprostheses as a standard of care — safe, reliable, and accessible to every patient who needs one.
Why ABILITY
End-to-End Solution
From implantable sensing electronics integration to neural data decoding, we own the entire platform — enabling tight optimisation across hardware, firmware, and AI for speech, movement, and future clinical applications.
Complete Neural Datasets
At its core, the ABILITY platform captures and transmits lossless high fidelity brain signals, using a proprietary laser-based optical data link that enables real-time neural data transmission through intact skin.
Designed with the patient at the center
The device is entirely implanted under the scalp — reducing infection risk and enabling seamless daily life.
Electrode Agnostic
Our platform is electrode-agnostic by design, matching the optimal neural interface to each clinical application. For speech, we have chosen high-density ECoG: high-resolution neural recordings with proven long-term stability, offering the best balance between signal quality and safety.
Real-time Output
Our goal is real-time, natural output — starting with fluent speech as our first clinical application, and extending to movement and beyond. Conversation and action at the speed of thought.
Our Journey
Foundations laid
Professor John Donoghue, widely regarded as the father of brain-computer interfaces, joins the Wyss Center for Bio and Neuroengineering in Geneva as founding director and designs the 'perfect' fully implantable, high-fidelity BCI — the system that would become ABILITY.
The vision is born
A multidisciplinary programme is launched at the Wyss Center to translate Donoghue's architecture into a clinical implant, with communication restoration as the first application. The team brings together expertise in neuroscience, implantable electronics, optical data transmission and neural decoding — the foundations of the platform, with an architecture built to extend from communication to movement and beyond.
Proving the impossible
In a landmark clinical study, Wyss Center scientists and engineers (now ABILITY) enabled a fully paralysed person living with amyotrophic lateral sclerosis (ALS) to communicate using implanted electrodes, modulating neural activity to produce yes/no responses for more than two years in a home setting.
This study demonstrated that BCI can restore function in complete locked-in state, and directly informed the design of the ABILITY platform. Published in Nature Communications.
Pioneering research at the Wyss Center
Under the umbrella of the Wyss Center, the project grows into a world-class research programme. A skilled team develops the core technology — from implantable electronics and optical data links to advanced neural decoding algorithms.
The programme achieves major milestones, including several pre-clinical trials in sheep and monkey models that validate the safety and performance of the device.
ABILITY Neurotech is born
The ABILITY BCI project spins out from the Wyss Center as ABILITY Neurotech — an independent company with a clear mission: to bring a fully implantable brain-computer interface to market that restores communication and movement for patients.
Based at Campus Biotech in Geneva, the skilled founding team brings together deep expertise in neuroscience, medical device engineering, machine learning, quality, and regulatory affairs.
First-in-Human technical file submitted
After completing a rigorous verification campaign, ABILITY submits its Investigational Medical Device Dossier (IMDD) technical file, marking a decisive step toward clinical trials.
In parallel, ABILITY submits a Breakthrough Device Designation (BDD) request to the U.S. FDA, reserved for medical devices addressing serious unmet needs — accelerating development, review and patient access.
Next stop: First-in-Human
Short-term intra-operative studies commence in Munich, May 2026. In parallel the milestone chronic First-in-Human implantation will be carried out in September 2026 in collaboration with BCI centers of excellence TU Graz (Austria) and UMC Utrecht (Netherlands).
These are significant achievements en route to patient impact and ultimate system regulatory approval.
How the ABILITY platform works
From implantation to signal acquisition to data transmission across the scalp — see the full journey of a neural signal through the ABILITY platform.